C.E.S. TABLETS 0.9 MG
CONJUGATED ESTROGENS : 0.9 MG · DIN 02230892 · VALEANT CANADA LP / VALEANT CANADA S.E.C.
Health Canada status: CANCELLED POST MARKET
What is C.E.S. TABLETS?
C.E.S. TABLETS 0.9 MG contains CONJUGATED ESTROGENS : 0.9 MG. It is listed in the Health Canada Drug Product Database under DIN 02230892, held by VALEANT CANADA LP / VALEANT CANADA S.E.C., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Jul-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is C.E.S. TABLETS used for?
C.E.S.® (conjugated estrogens tablets, CSD) is indicated for: Relief of menopausal and postmenopausal symptoms occurring in naturally or surgically induced estrogen deficiency states including vaginal and vulvar atrophy (with or without pruritus). Prevention and treatment of osteoporosis in naturally occurring or surgically induced estrogen-deficiency states in addition to other important therapeutic measures. Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. Atrophic vaginitis. In male patients: Inoperable progressing prostatic cancer (for palliation only when castration is not feasible, or when castration failed or delayed escape following a response to castration occurred).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02230892 |
|---|---|
| Brand name | C.E.S. TABLETS |
| Generic / active ingredient | CONJUGATED ESTROGENS : 0.9 MG |
| Manufacturer | VALEANT CANADA LP / VALEANT CANADA S.E.C. |
| Strength | 0.9 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03CA57 CONJUGATED ESTROGENS |
| AHFS class | 68:16.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Jul-2014 |
| Original market date | 1997-03-14 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02230892 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2230892 |
| Brand name | C.E.S. TABLETS |
| Active ingredient / INN | CONJUGATED ESTROGENS : 0.9 MG |
| ATC code | G03CA57 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03 |
| AHFS class | 68:16.04 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | VALEANT CANADA LP / VALEANT CANADA S.E.C. |
How is it administered?
Prescribe at lowest effective dose for shortest period. In patients with intact uteri, supplement with a progestin to prevent endometrial hyperplasia. Administered orally.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
STORAGE AND STABILITY. SPECIAL HANDLING INSTRUCTIONS
How is it supplied?
null
Which pack is which?
| Strength on the label | 0.9 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | null |
| Storage | STORAGE AND STABILITY. SPECIAL HANDLING INSTRUCTIONS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Liver dysfunction, estrogen-dependent neoplasia, endometrial hyperplasia, breast cancer, undiagnosed genital bleeding, pregnancy, active/past VTE or arterial thromboembolic disease, breastfeeding.
Warnings and precautions
Increased risk of MI, stroke, invasive breast cancer, and VTE. Increased risk of dementia in women >65. Should not be used for cardiovascular disease prevention.
What can be used instead?
Other Canadian products sharing ATC code G03CA57 CONJUGATED ESTROGENS. 4 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PREMARIN | 0.3 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 02414678 |
| PREMARIN | 1.25 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 02414694 |
| PREMARIN INTRAVENOUS | 25 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02043386 |
| PREMARIN VAGINAL CREAM | 0.625 MG | Cream | PFIZER CANADA ULC | MARKETED | DIN 02043440 |
| APO-CONEST TAB 0.3MG | 0.3 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798231 |
| APO-CONEST TAB 0.625MG | 0.625 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798223 |
| APO-CONEST TAB 0.9MG | 0.9 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798215 |
| APO-CONEST TAB 1.25MG | 1.25 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798207 |
| APO-CONEST TAB 2.5MG | 2.5 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798193 |
| C.E.S. | 0.625 MG | TABLET | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00265470 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.